Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

NCT04833023 is registered in ClinicalTrials.gov with Tan Tock Seng Hospital as lead sponsor.

NCT NCT04833023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04833023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial
Lead sponsor
Tan Tock Seng Hospital
Phase
Phase 3
Overall status
Completed
Start date
May 18, 2022
Completion date
September 25, 2025
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, end-stage organ disease, haloperidol, hyperactive delirium, olanzapine